Prophylactic or therapeutic administration of Holarrhena floribunda hydro ethanol extract suppresses Complete Freund’s Adjuvant-induced arthritis in Sprague-Dawley rats

Stephen Antwi  
Centre for Plant Medicine Research (CPRM)

Daniel Oduro-Mensah (danoduro-mensah@ug.edu.gh)  
Department of Biochemistry, Cell and Molecular Biology, School of Biological Sciences, University of Ghana  
https://orcid.org/0000-0003-4492-2202

David Darko Obiri  
Kwame Nkrumah University of Science and Technology

Clara Lewis  
Centre for Plant Medicine Research (CPRM)

Ebenezer Oduro-Mensah  
Ga-East Municipal Hospital

Augustine Ocloo  
University of Ghana

Laud Okine  
University of Ghana

Research Article

Keywords: Arthritis, COVID-19, Cytokines, Holarrhena floribunda, Immunomodulation, Inflammation

DOI: https://doi.org/10.21203/rs.3.rs-126064/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Ethnopharmacological relevance In Ghanaian folk medicine, *Holarrhena floribunda* has anecdotal use for the treatment of inflammatory conditions. A hydro ethanol extract of the stem bark has previously been shown to be effective in the management of acute inflammation and anaphylaxis in rodents.

Aim of the study This study was aimed at evaluating the usefulness of *H. floribunda* stem bark hydro ethanol extract (HFE) for the management of chronic inflammation in a murine model.

Materials and Methods Anti-arthritic effect of the extract was evaluated using Complete Freund's Adjuvant-induced arthritis in male Sprague-Dawley rats. Using both prophylactic and therapeutic treatment models, parameters assessed included oedema, serology of inflammatory response, radiology, bone tissue histology and haematology. Data were analysed by ANOVA followed by Tukey's multiple comparisons *post hoc* test.

Results HFE at 50–500 mg/kg dose-dependently \([ P \geq 0.0354 \text { (prophylactic) and } P \geq 0.0001 \text { (therapeutic) }] \) inhibited swelling of the injected paw upon prophylactic \([ \leq 81.26 \% (P<0.0001) ] \) or therapeutic \([ \leq 67.92 \% (P<0.01) ] \) administration — and prevented spread of arthritis to the contralateral paw. Inflammation alleviation activity of HFE was further demonstrated by decrease in arthritis score, radiologic score and erythrocyte sedimentation rate. HFE at all doses significantly reduced serum IL-1\( \alpha \) \((P<0.0197)\), and 500 mg/kg HFE reduced serum IL-6 \((P=0.0032)\). In contrast, serum concentrations of IL-10, protein kinase A and cyclic adenosine monophosphate were enhanced \((P \leq 0.0436)\). HFE consistently showed better prophylactic activity than when administered therapeutically.

Conclusions The data demonstrate that HFE suppresses CFA-induced arthritis and modulates regulators of inflammation; including IL-1\( \alpha \), -6 and -10 which also play mediatory roles in several immune response pathways. These make HFE a strong candidate for development as an agent for management and modulation of inflammation and the inflammatory response, including immune response-related adverse events such as seen in severe COVID-19.

1. Introduction

Currently, chronic diseases are the major cause of mortality worldwide (WHO, 2019). Inflammation has been shown to have a strong and consistent relationship with several chronic disease conditions (Aggarwal & Gehlot, 2009; Peter J Barnes, 2016; Mantovani et al., 2008; Pahwa & Jialal, 2019; Zhong & Shi, 2019). In addition to reduced quality of life due to disability, the economic burden of chronic inflammatory diseases is clearly demonstrable (Brooks, 1998; Straub & Schrading, 2016; Williams & Meyers, 2002; Zhang & Anis, 2011). Long-term treatment options, however, are still not optimal. With respect to rheumatoid arthritis, for example, oral anti-rheumatics have demonstrated limited efficacy and significant toxicity in humans (Dhikav et al., 2002; Hudson & Hawkey, 1993; Laine et al., 2006; Rein & Mueller, 2017; Xu et al., 2009; Xue et al., 2008). As inflammation-related acute or chronic conditions emerge and/or persist, it is important to continually prospect for treatment alternatives that may have relatively acceptable or no undesirable side effects. Such agents should be more suitable for safe prophylactic use or long-term management of acute and chronic inflammatory diseases.
Holarrhena oribunda, a medium-sized tree of the family Apocynaceae, has anecdotal use in Ghanaian folk medicine for the treatment of inflammation-related conditions. Using murine models of acute inflammation, data from our laboratory show that the hydro ethanol extract of H. floribunda stem bark has both prophylactic and therapeutic anti-inflammatory and antihistaminic effects, showing (1) protection from anaphylaxis by suppressing sepsis or systemic shock due to lipopolysaccharide and compound 48/80, respectively, and (2) inhibitory effect on paw oedema due to phlogistic agents including carrageenan, histamine, serotonin and prostaglandin E₂ (Antwi et al., 2020). The present study was designed to evaluate the in vivo anti-inflammatory activity of H. floribunda stem bark in a chronic inflammation model, and to identify mediators of the observed biological activity. Prophylactic and therapeutic anti-inflammatory activities of HFE were assessed.

2. Materials And Methods

2.1 Preparation of Extract

Holarrhena floribunda (G.Don) stem bark was collected from Kwahu-Asakraka (6°38¢02.6N²;0°41¢37.5°W), Eastern Region, Ghana. The plant name has been checked with http://www.theplantlist.org on 28th Nov. 2020. The plant material was identified and authenticated by the Plant Development Department of Centre for Plant Medicine Research (CPMR), Mampong-Akuapem, Ghana. The Plant Development Department has a licence from the Forest Services Division of Forestry Commission of Ghana to source for plant material from the arboretum of CPMR and the wild. A voucher specimen (no. 05/13) is deposited at the herbarium of CPMR. The material was washed thoroughly, air-dried and milled into coarse powder. Powdered stem bark (1 kg) was macerated in 5 L of 70% v/v ethanol with periodic stirring, decanted after 72 h and filtered through Whatman no 1 filter paper. Ethanol was evaporated (BUCHI Rotavap; Flawil, Switzerland). The aqueous concentrate was lyophilised, stored at 4°C and was reconstituted in sterilised distilled water for use as H. oribunda bark hydro ethanol extract (HFE).

2.2 Experimental Animals

All animal experiments were approved by the Ethics Committee of CPMR (approval number CPMR/M.6-PT3/2018). Male Sprague Dawley rats (200–220 g) were housed in the Animal Experimentation Unit of CPMR under ambient laboratory conditions: temperature 26 ± 2 °C, relative humidity 60–70%, normal light/dark cycle of 12 h each). Animals were randomly assigned to groups labelled either as control (vehicle or positive) or extract treatment groups. All animals were acclimatized for seven days in the designated experimentation room before the start of experiments. The animals were trained to allow cooperation with restraint and other handling procedures. Throughout the period, the animals were handled in accordance with internationally accepted principles of laboratory animal use and care (EEC Directive 2010/63/EU). The animals were allowed access ad libitum to pelleted feed (Agricare Ghana Ltd) and sterilized drinking water. The wellbeing of animals used in all experimental procedures was continuously monitored at least at 12-h intervals. Death of an animal was not used as the endpoint in any experiment. Animals found to be visibly morbid were euthanised to alleviate pain and distress. Criteria for euthanasia included body temperature below 34 °C, laboured respiration, reduced exploration, reduced grooming, inability to access food and water, and lack of response to manipulation (Franco et al., 2012; Ray et al., 2010). Euthanasia was by pentobarbital sodium i.p., 800 mg/kg (Zatrouch et al., 2017).
2.3 Induction of Arthritis

Complete Freund's adjuvant (CFA) was constituted as a 5 mg/ml suspension of heat-killed *Mycobacterium tuberculosis* triturated in sterile paraffin oil (KAMA Pharmaceutical Industries, Ghana) (Pearson, 1956). Arthritis was induced in the Sprague-Dawley rats (SDRs) by a one-time sub-plantar injection of the right hind paw with 100 µl CFA. Non-arthritic control animals received 100 µl of sterile paraffin oil (KAMA Pharm, Ghana), subsequently referred to as Incomplete Freund's adjuvant (IFA). A plethysmometer (Ugo Basile, Italy) was used to measure paw volume for both the injected and contralateral hind paws before injection of CFA or IFA, and then every other day after that for 28 days (Binder & Walker, 1998) The oedema component of inflammation was computed as the percent change in paw volume from day zero at each time point.

2.4 Administration of Extract

Each treatment group had six rats. Dexamethasone (Sigma-Aldrich, St Louis) was used as the positive control agent. Preparations for treatment (dexamethasone or HFE) were freshly constituted and administered daily by oral gavage. For the prophylactic drug protocol, dexamethasone (0.3 mg/kg b.w.) or HFE (50, 200 or 500 mg/kg b.w.) was administered 1 h before induction of arthritis. In the therapeutic protocol, treatment started on day 14 after induction of arthritis. In both cases, treatment was terminated on day 28.

2.5 Assessment of Anti-arthritic Effect

Protective or curative properties of HFE were assessed using four indices of arthritic damage: (1) maximal and total oedema, (2) arthritis score from photographs and X-ray images, (3) histopathology and (4) haematology.

2.5.1 Maximal and total oedema

Maximal and total oedema responses were compared between drug-treated groups and untreated control groups. To obtain oedema responses, the foot volumes were individually normalized as percentage of change from the value at day zero, and then averaged for each treatment group. Mean percent change in paw volume for each treatment was calculated as:

\[
\% \text{ Change in paw volume} = \left( \frac{PV_t - PV_0}{PV_0} \right) \times 100
\]

Where \( PV_0 \) and \( PV_t \) are respectively the paw volumes at times 0 and timepoint \( t \), respectively.

Total oedema induced was determined as area under the time course curves (AUC). Percent inhibition of total oedema for each treatment was calculated as:
2.5.2 Arthritis score

Severity of arthritis on day 28 was represented by arthritis scores for the injected and contralateral hind paws, assessed by photography and radiography (Cai et al., 2007). The extent of oedema was scored blindly from photographs (FE-5050, OLYMPUS, Tokyo, Japan) on a scale of 0–4 interpreted as 0 = un-injected paw with no swelling; 1 = slight swelling and/or erythema; 2 = low to moderate oedema and/or erythema; 3 = pronounced oedema and/or erythema with limited joint use; 4 = excess oedema and/or erythema with joint rigidity.

X-ray images were taken on industrial X-ray film (Fuji Photo Film, Tokyo, Japan) using an X-ray machine (Philips, Eindhoven, Netherlands) operated at 52 kV against 3.2 mA s\(^{-1}\) with a tube-to-film distance of 110 cm for lateral projection. Severity of joint and bone deformation was blindly scored according to the extent of osteoporosis, joint spaces and joint structure (Pohlers et al., 2007) on a scale of 0–4, interpreted as 0 = no degenerative joint changes; 1 = slight soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, subluxation or degenerative joint changes; 2 = low to moderate soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, subluxation or degenerative joint changes; 3 = pronounced soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, subluxation or degenerative joint changes; 4 = excess soft tissue volume, joint space, subchondral erosion, periostitis, osteolysis, subluxation or degenerative joint changes.

2.5.3 Histology

Rats were euthanized by cervical dislocation on day 28. The injected paws were amputated above the ankle and fixed in 4 % formalin. Hair on the paws were trimmed and the paws were placed in decalcifying solution (14 % EDTA) for 10 days. Decalcified paws were embedded in paraffin, sectioned at 4 µm, stained with haematoxylin and eosin, and observed under a light microscope (100 × magnification; Dialux 22; Leitz, Wetzlar, Germany). Changes in joint bone tissue were scored blindly on a scale of 0–3, interpreted as 0 = absence of synovial hyperplasia, pannus, bone erosion and inflammatory cells; 1 = mild presence of synovial hyperplasia, pannus, bone erosion, and presence of inflammatory cells; 2 = moderate presence of synovial hyperplasia, pannus, bone erosion, and presence of inflammatory cells; 3 = severe presence of synovial hyperplasia, pannus, bone erosion, and presence of inflammatory cells.

2.5.4 Haematology

Blood was collected on day 28 for both prophylactic and therapeutic approaches by tail bleeding into EDTA tubes (Cland Medical Instuments, Zhejiang, China) for haematological analysis (Abacus 380, Budapest, Hungary) or estimation of erythrocyte sedimentation rate (Curtin Matheson Scientific, Houston, TX, respectively.)
2.6 Assessment of Serum Indicators: IL-1α, IL-6, IL-10, PKA, PKC, cAMP

Blood collected from the tail vein into vacutainer gel and clot activator tubes (SG Biotech, Middlesex, England) on day 28 were allowed to clot at room temperature and centrifuged at 1000×g for 10 min to obtain serum obtained. Serum levels of interleukin 1-alpha, interleukin 6, interleukin 10 (Abcam Plc, Cambridge, UK), protein kinases A and C, and cyclic adenosine monophosphate (MyBioSource, San Diego, CA) were each measured in triplicate with the appropriate rat ELISA kit according to the manufacturer’s guidelines.

2.7 Statistical Analyses

All graphing and analyses were performed with GraphPad Prism for Windows Version 8 (GraphPad, San Diego, CA). Data were analysed by one-way or two-way (treatment x time) repeated measure analysis of variance followed by Tukey's multiple comparisons test. Indications of significance are reported as multiplicity adjusted P values. Unless otherwise stated, all comparisons described are relative to the CFA arthritic control group. Differences in means were considered statistically significant at P ≤ 0.05.

3. Results

3.1 Maximal and Total Oedema

Paw oedema as a measure of arthritis development in the arthritis control group showed that arthritis progression was in two phases: an acute inflammatory stage between days 2–8, followed by further increase which indicated progression to chronic polyarthritis from day 14 and peaking on day 20 (Fig. 1a & e). In the injected paw, maximal oedema for the prophylactic and therapeutic treatment models were 261.57 % (Fig. 1a) and 219.35 % (Fig. 1e) of baseline paw volume, respectively. In the contralateral paw, maximal oedema values were 26.78 % of baseline for the prophylactic model (Fig. 1c) and 54.98 % for the therapeutic model (Fig. 1g).

HFE exhibited anti-arthritic activity (Fig. 1b & f) and inhibited spread of arthritis to the contralateral paw (Fig. 1d & h) in the prophylactic treatment model. In the acute inflammation phase, 500 mg/kg HFE reduced total oedema by 56.59 %, similar (P = 0.9632) to oedema reduction by dexamethasone (48.77 %) (Fig. 1b). HFE reduced oedema in the polyarthritis phase by ≥ 53.94 % (Fig. 1 B), with reduction at 500 mg/kg (92.56 %) being higher (P = 0.3080) than reduction by dexamethasone (77.99 %). Again, HFE reduced contralateral oedema due to polyarthritis by ≥ 32.49 % (Fig. 1d), with reduction by 500 mg/kg HFE (94.15 %) significantly higher (P < 0.0001) than reduction by dexamethasone (49.73 %). There were no differences (P > 0.9993) in oedema between the treatment groups during the acute inflammation phase of the therapeutic model (Fig. 1f & h). In the polyarthritis phases, HFE inhibited oedema by ≥ 34.69 % for the injected paw and ≥ 48.79 for the contralateral paw (Fig. 1f & h). Inhibition by 200 or 500 mg/kg HFE was not different (P ≥ 0.6142) from inhibition by dexamethasone for both.

3.2 Arthritis Score

3.2.1 Photograph scoring
The IFA control group had the lowest arthritis score for the injected (Fig. 2a) and contralateral (Fig. 2b) paws, with no visible signs of oedema or erythema on day 28 (Plate 1 A). The untreated CFA control group scored highest, with photographs showing severe erythema, lesions and/or swelling of soft tissue in both paws for the prophylactic and therapeutic models (Plate 1 B). Dexamethasone-treated rats showed moderate levels of erythema, soft tissue swelling and lesions in both the injected and contralateral limbs (Plate 1 C). In all cases, administration of HFE reduced the arthritis scores and inhibited the development of erythema, lesion and swelling (Plate 1 D–I) in both the injected and contralateral paws. Efficacy of HFE appeared to increase when administered prophylactically (Fig. 2), whereas dexamethasone did not show any such indication.

3.2.2 Radiography

IFA control rats showed no indication of joint damage or osteolysis of bone in the injected or contralateral hind paws (Plate 2 A, Table 2). In the untreated CFA control group, there was evidence of severe periarticular soft tissue swelling in both the injected and contralateral hind limbs (Plate 2 B). Osteolysis of tarsal and metatarsal bones, as evidenced by reduced bone density and demineralization of the bones, was observed in the untreated CFA group. In addition, there were signs of inflammation at the metatarsal-phalangeal joint and the regions in-between the bones of the phalanges and the metatarsals. Erosion of the phalangeal bone was observed, with moderate affection of the distal tibia and joint deformation. The untreated CFA group radiographs recorded the highest arthritis blind scores (Table 1). Administration of dexamethasone resulted in reduced soft tissue swelling, osteolysis of tarsal and metatarsal bone, moderate affection of distal tibia, reduced joint deformation (Plate 2 C) and reduced arthritic score (Table 1). Prophylactic (Plates 2 D–F) or therapeutic (Plates 2 G–I) HFE administration reduced peri-articular soft tissue swelling, radiographic joint lesion, bone demineralization and erosion, and joint deformation. The HFE treated rats received lower scores compared to the CFA control group (Table 1), and scores for 500 mg/kg HFE were at least equal to dexamethasone scores.

3.2.3 Histology

IFA control rats had intact bone structure with no visible necrotising granulomatous inflammation and mononuclear cell infiltration (Plate 3 A). The CFA arthritic control group showed necrotising granulomatous inflammation of the synovial membrane and bone erosion (Plate 3 B). There was severe mononuclear infiltration with mostly lymphocytes and multinucleated giant cells, as well as vascular proliferation and presence of macrophages. Arthritic changes observed in the CFA control group were ameliorated on treatment with dexamethasone or HFE (Plate 3, Table 2).

3.3 Haematology

Induction of arthritis increased \((P \leq 0.0004)\) white blood cell (WBC) count and erythrocyte sedimentation rate (ESR), whilst decreasing haematocrit \((P < 0.0001)\) in the CFA control relative to the IFA control (Table 3). Prophylactic HFE administration at 200 or 500 mg/kg had a modulatory effect, reducing WBC \((P \leq 0.0144)\) and ESR \((P < 0.0001)\) — and increasing haematocrit \((P < 0.0011)\) compared to the CFA control. Therapeutic HFE
reduced ESR ($P \leq 0.0001$) and increased haematocrit ($P \leq 0.0185$). Unlike therapeutic dexamethasone, prophylactic dexamethasone resulted in an indication of leukopenia ($P < 0.0001$).

3.4 Prophylactic effect of *Holarrhena floribunda* on serum IL-1α, IL-6 and IL-10 levels

Serum IL-1α in the CFA control was $104.05 \pm 27.46$ pg/ml, compared to $5.23 \pm 0.59$ pg/ml in the IFA control group (Fig. 3 A). Treatment with HFE or dexamethasone resulted in reduced ($P \leq 0.0197$) serum levels of the marker relative to the CFA control. Dexamethasone recorded IL-1α serum concentration of 21.53 pg/ml, which was not significantly different ($P \geq 0.5504$) values for HFE.

Serum IL-6 increased from $0.45 \pm 0.04$ pg/ml in the IFA non-arthritis control group to $3.72 \pm 0.30$ pg/ml in the CFA arthritic control (Fig. 3 B). Treatment with HFE led to reductions in serum IL-6 concentration, which was significant ($P = 0.0032$) only for the 500 mg/kg dose. Dexamethasone reduced ($P = 0.0149$) serum IL-6, but the effect was not different ($P \geq 0.4348$) from any of the HFE doses.

IL-10 concentration in serum from the CFA and IFA control groups were $25.17 \pm 5.17$ pg/ml and $657.66 \pm 21.73$ pg/ml, respectively (Fig. 3 C). Dexamethasone increased ($P = 0.0003$) serum IL-10. Similarly, HFE administration increased serum IL-10, but this was significant ($P = 0.0462$) only for the 500 mg/kg dose. The value for dexamethasone was not significantly different ($P = 0.1079$) from 500 mg/kg HFE.

3.5 Effect of *Holarrhena floribunda* on enzymes and secondary messengers

Arthritic CFA control animals showed a reduction in serum PKA, approximately three-fold from $25.41 \pm 2.07$ ng/ml to $7.71 \pm 0.64$ ng/ml (Fig. 4 A). Administration of HFE at 200 or 500 mg/kg increased serum PKA ($P \leq 0.0393$). The value for dexamethasone (17.7 ng/ml) was not different ($P \geq 0.3779$) from the values for the 200 and 500 mg/kg HFE doses.

Serum PKC was elevated at least four-fold, from $0.38 \pm 0.04$ ng/ml in the IFA non-arthritis control group to $1.78 \pm 0.37$ ng/ml in the untreated CFA control (Fig. 4 B). Both dexamethasone and 500 mg/kg HFE reduced serum PKC activity, to 38 % and 69 % of the CFA value, respectively. However, neither of the measured effects was significant ($P \geq 0.0958$).

Induction of arthritis reduced serum cAMP from $16.53 \pm 1.72$ pg/ml in the IFA non-arthritis control to $4.95 \pm 0.32$ pg/ml in CFA arthritic control (Fig. 5). Treatment with HFE increased ($P \geq 0.0938$) serum cAMP levels compared to the CFA control group. The increase due to dexamethasone was also not significant ($P = 0.4207$).
4. Discussion

In this study, the inhibitory effect of *Holarrhena floribunda* stem bark extract (HFE) on chronic inflammation was evaluated. Sprague-Dawley rats were used as the experimental animal. The Complete Freund's Adjuvant (CFA)-induced arthritis model was adopted because it has several characteristics, including serology, in common with human rheumatoid arthritis (Li et al., 2010; Stils Jr., 2005; Voon et al., 2017). Adjuvant-induced arthritis is a T lymphocyte-dependent chronic inflammatory condition that develops in two phases: an acute, peri-articular inflammation phase followed by a chronic phase with joint and bone involvement (Baddack et al., 2013; Bevaart et al., 2010). Both phases were observed in this study. Also, biological and immunological features of the immune response to CFA (Rampasath et al., 2006; Stils Jr., 2005), such as lesions or ulcers at the site of injection, peri-articular erythema, oedema, reduction of paw function and evidence of hyperalgesia were observed in arthritic control animals. The development of contralateral swelling at the CFA dose used in this study is consistent with previous observations (Kozin et al., 1976; Shenker et al., 2003; Yu et al., 1996). Alleviation of the listed features were assessed in drug/extract-treated animals.

HFE showed its strongest anti-arthritic activity at the 500 mg/kg dose, at least similar to dexamethasone in both the prophylactic and therapeutic treatment models (Fig. 1 & 2; Table 1). Administration of HFE inhibited the development of paw oedema in the acute inflammation phase (Fig. 1; Plate 1; Table 1 & 2) and suppressed development of polyarthritis in the chronic phase (Fig. 1 & 2; Plate 1–3). Short-term inflammatory responses, as seen in the acute inflammation phase, are typically mediated by histamine via the H1 receptor (Schaefer et al., 1999; Wilhelm, 1973). In a previous report, we have demonstrated the strong antihistaminic activity of HFE (Antwi et al., 2020). We acknowledge that data on the role of histamine in arthritis progression have traditionally been contradictory (Adlesic et al., 2007). However, more recent reports and analyses suggest strong links, depending on histamine receptor type expression, between histamine and various hypersensitivity response mediators, particularly leukocytes and T cells (Saeki et al., 2016) which are involved in the development of CFA-induced arthritis. It is our opinion that the contribution of histamine, via the H1 receptor, to the acute oedema following CFA administration in the adjuvant-induced arthritis model cannot be overlooked (Nasuti et al., 2019; Schaefer et al., 1999; Simons, 2004). More relevant to the chronic inflammation phase and human rheumatoid arthritis, we point to the role of histamine receptors, particularly the H4 receptor, in affecting levels of both pro- and anti-inflammatory cytokines by T cell modulation (Dunford et al., 2006; Saeki et al., 2016; Tamaka et al., 2015). The ligand-bound H4 receptor is reported to play both autocrine and paracrine roles (Thangam et al., 2018) in the progression of long-term inflammatory responses, by mediating (1) MAPK activation; (2) enhanced Ca\(^{2+}\) release; (3) mast cell activation for expression of pro-inflammatory cytokines (Hofstra et al., 2003; Jemima et al., 2014; Lippert et al., 2004; Mirzahosseini et al., 2013); and (4) decrease in levels of anti-inflammatory cytokines (Tamaka et al., 2015).

We have previously suggested that HFE may be useful against COVID-19-associated inflammation (Antwi et al., 2020). Histamine involvement in COVID-19 progression has been suggested and/or described in several reports (P. J. Barnes, 1991; Hill, 1992; Kilinc et al., 2020; Kritas et al., 2020). The anti-histaminic potential of HFE, again demonstrated in this study by HFE inhibition of both acute and chronic oedema due to CFA, could play a role in modulating the dysregulated immune response in COVID-19.
Another feature of chronic inflammation pathologies is contribution of the vasculature to the disease process by formation of hyperpermeable vessels with poor blood flow allowing the leakage of blood components and contributing to oedema (Claesson-Welsh, 2015). Such vascular proliferation is also seen in CFA-induced inflammation (Walsh et al., 2005). The ability of HFE to reduce this pathology is suggested by the observed reduction in erythema and oedema relative to the arthritic control animals (Plate 1). The anti-arthritic effect of HFE was further demonstrated by inhibition of necrosis, vascular proliferation and bone loss at the joints (Plate 2 & 3; Table 1) (Bromley & Woolley, 1984; Kuratani et al., 1998; Suzuki et al., 2007; Walsh et al., 2005), leading to preservation of joint integrity (W. B. van den Berg, 2001) (Lubberts et al., 2004). HFE evidently limited osteoclast differentiation and activity, shown by reduction in the extent of bone resorption (Plate 2). This inhibitory effect is indicative of interaction between HFE and factors including receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL), tumour necrosis factor-α (TNF-α), and prostaglandin E₂ (PGE₂), all of which promote osteoclast differentiation and action leading to bone resorption (W. Berg, 2001; Lubberts et al., 2004).

Several lines of evidence point to pro-inflammatory cytokines, including IL-1, IL-2, IL-6 and TNFα, as major players in the onset and progression of adjuvant-induced arthritis (Bonecchi et al., 1998; Brennan & McInnes, 2008; Chu et al., 1991; Niki et al., 2010). In this study, HFE suppressed serum levels of IL-1α and IL-6, but enhanced IL-10 (Fig. 3). The ability of HFE to suppress the pro-inflammatory IL-6 and increase serum IL-10 is suggestive of immunomodulatory potential. Serum PKC activity was reduced (Fig. 4 A), possibly due to the potentially inhibitory effect of HFE on Ca²⁺ release due to the antihistaminic activity. PKC is activated by calcium ion and has been shown to be involved in propagation of the immune inflammatory (Gray et al., 2013; Kim et al., 2013; Medina, 2009; Ren et al., 2014). In contrast, HFE increased serum levels of PKA and cAMP (Fig. 4 B & C). cAMP and its effector, PKA, are implicated in the resolution of acute inflammation (Lima et al., 2017) and are generally regarded as anti-inflammatory (Campo et al., 2012; Oldenburger et al., 2012; Wang et al., 2020). Interestingly, cAMP has been shown to inhibit histamine release from human mast cells (Barreiro-Costa et al., 2014) and is reported to be key in several endogenous processes involved in preventing acute inflammation from progressing to deleterious chronic inflammation (Moore & Willoughby, 1995). Indeed, HFE reduced WBC and ESR (Table 3), both of which may be used as markers of inflammation status (Carr et al., n.d.; Farhangi et al., 2013; Harrison, 2015; Ingelsson et al., 2005; Kounis et al., 2014; Ong et al., 2015; Watson et al., 2012). Taken together, the data strongly support that HFE has anti-oedematogenic, anti-histaminic, anti-inflammatory, and immunomodulatory activities.

4.1 Conclusion

The hydroethanolic extract of *Holarrhena floribunda* has inhibitory effects on chronic inflammation. In both the prophylactic and therapeutic models used in this study, HFE has shown potent anti-inflammatory and immunomodulatory activities relative to serum levels of histamine, IL-1α, IL-6, IL-10, cAMP and protein kinases A and C. In addition to the evidence to support the usefulness of HFE in management of rheumatoid arthritis and similar chronic inflammation conditions, we suggest that HFE may be useful for both prophylactic and therapeutic management of COVID-19 associated inflammation.
Glossary

cAMP, cyclic AMP; CFA, complete Freund’s adjuvant; COVID-19, corona virus disease 2019; ESR, erythrocyte sedimentation rate; IFA, incomplete Freund’s adjuvant; IL, interleukin; MAPK, mitogen-activated protein kinase; PKA/PKC, protein kinase A/C; PGE$_2$, prostaglandin E$_2$; RANKL, receptor activator of nuclear factor kappa B (NF-$\kappa$B) ligand; TNF$\alpha$, tumor necrosis factor alpha

Declarations

AUTHORS CONTRIBUTIONS

SA designed and carried out laboratory work for this study, provided resources for the study, analysed the data and drafted the manuscript. DOM provided resources for the study, analysed the data, reviewed and prepared the final manuscript. DDO conceptualized the study, provided resources, supervised the work and reviewed the draft manuscript. CL contributed to drafting the manuscript. EOM, AO and LKNO reviewed and edited the final manuscript. All authors have read and approved the manuscript.

ACKNOWLEDGEMENTS

The authors acknowledge the support and collaboration of scientists and technicians at the Animal Experimentation Unit of the Centre for Plant Medicine Research, Mampong-Akuapem, Ghana.

FUNDING

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST

None.

References

Adlesic, M., Verdrengh, M., Bokarewa, M., Dahlberg, L., Foster, S. J., & Tarkowski, A. (2007). Histamine in rheumatoid arthritis. Scandinavian Journal of Immunology, 65(6), 530–537.

Aggarwal, B. B., & Gehlot, P. (2009). Inflammation and cancer: how friendly is the relationship for cancer patients? Current Opinion in Pharmacology, 9(4), 351–369.
Antwi, S., Oduro-Mensah, D., Darko Obiri, D., Osafo, N., Antwi, A. O., Owusu, A. H., Ocloo, A., & Okine, L. (2020). Hydro ethanol extract of Holarrhena oribunda stem bark exhibits anti-anaphylactic and anti-oedematogenic effects in murine models of acute in ammation. Under Review. https://doi.org/10.21203/rs.3.rs-110342/v1

Baddack, U., Hartmann, S., Bang, H., Grobe, J., Loddenkemper, C., Lipp, M., & Müller, G. (2013). A chronic model of arthritis supported by a strain-speciﬁc periarticular lymph node in BALB/c mice. Nature Communications, 4(1), 1–10.

Barnes, P. J. (1991). Histamine receptors in the lung. Agents and Actions, 33, 103–122. https://doi.org/10.1007/978-3-0348-7309-3_9

Barnes, Peter J. (2016). Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 138(1), 16–27.

Barreiro-Costa, O., Tobío, A., Alfonso, A., & Botana, L. M. (2014). Different Role of cAMP Pathway on the Human Mast Cells HMC-1560 and HMC-1560, 816 Activation. Journal of Cellular Biochemistry, 115(5), 896–909.

Berg, W. (2001). van den Berg, W. B. Uncoupling of inﬂammatory and destructive mechanisms in arthritis. Semin. Arthritis Rheum. 30, 7-16. Seminars in Arthritis and Rheumatism, 30, 7–16. https://doi.org/10.1053/sarh.2001.23704

Bevaart, L., Vervoordeldonk, M. J., & Tak, P. P. (2010). Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis & Rheumatism, 62(8), 2192–2205.

Binder, W., & Walker, J. S. (1998). Effect of the peripherally selective κ-opioid agonist, asimadoline, on adjuvant arthritis. British Journal of Pharmacology, 124(4), 647–654. https://doi.org/10.1038/sj.bjp.0701874

Bonecchi, R., Bianchi, G., Bordignon, P. P., D’Ambrosio, D., Lang, R., Borsatti, A., Sozzani, S., Allavena, P., Gray, P. A., Mantovani, A., & Sinigaglia, F. (1998). Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. The Journal of Experimental Medicine, 187(1), 129–134. https://doi.org/10.1084/jem.187.1.129

Brennan, F. M., & McInnes, I. B. (2008). Evidence that cytokines play a role in rheumatoid arthritis. The Journal of Clinical Investigation, 118(11), 3537–3545.

Bromley, M., & Woolley, D. E. (1984). Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis & Rheumatism: Ofﬁcial Journal of the American College of Rheumatology, 27(9), 968–975.

Brooks, P. M. (1998). The Heberden Oration 1997. Treatment of rheumatoid arthritis: from symptomatic relief to potential cure. British Journal of Rheumatology, 37(12), 1265–1271.

Campo, G. M., Avenoso, A., D’Ascoloa, A., Scuruchi, M., Prestipino, V., Nastasi, G., Calatroni, A., & Campo, S. (2012). The inhibition of hyaluronan degradation reduced pro-inﬂammatory cytokines in mouse synovial ﬁbroblasts subjected to collagen-induced arthritis. Journal of Cellular Biochemistry, 113(6), 1852–1867.

Carr, B., Akkiz, H., Guerra, V., Donghia, R., Yalçın, K., Karao, U., Altinta, E., Özakyol, A., H, Ş., Hy, B., Balkan, A., Uyanık, A., & Ekin, N. (n.d.). Erythrocyte Sedimentation Rate and C-Reactive Protein are Markers for Tumor
Aggressiveness and Survival in Patients with Hepatocellular Carcinoma Journal of Clinical Trials. 1–11. https://doi.org/10.35248/2167-0870.20.10.428

Chu, C. Q., Field, M., Feldmann, M., & Maini, R. N. (1991). Localization of tumor necrosis factor α in synovial tissues and at the cartilage–pannus junction in patients with rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 34(9), 1125–1132.

Claesson-Welsh, L. (2015). Vascular permeability—the essentials. Upsala Journal of Medical Sciences, 120(3), 135–143. https://doi.org/10.3109/03009734.2015.1064501

Dhikav, V., Singh, S., & Anand, K. (2002). Newer non-steroidal anti-inflammatory drugs: A review of their therapeutic potential and adverse drug reactions. J. Indian Acad. Clin. Med., 3, 332–338.

Dunford, P. J., O'Donnell, N., Riley, J. P., Williams, K. N., Karlsson, L., & Thurmond, R. L. (2006). The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells. The Journal of Immunology, 176(11), 7062–7070.

Farhangi, M. A., Keshavarz, S. A., Eshraghian, M., Ostadrahimi, A., & Saboor-Yaraghi Dr., A. A. (2013). White blood cell count in women: Relation to inflammatory biomarkers, haematological profiles, visceral adiposity, and other cardiovascular risk factors. Journal of Health, Population and Nutrition, 31(1), 58–64. https://doi.org/10.3329/jhpn.v31i1.14749

Franco, N. H., Correia-Neves, M., & Olsson, I. A. S. (2012). How “humane” is your endpoint? Refining the science-driven approach for termination of animal studies of chronic infection. PLoS Pathogens, 8(1), e1002399. https://doi.org/10.1371/journal.ppat.1002399

Gray, R. D., Lucas, C. D., MacKellar, A., Li, F., Hiersemenzel, K., Haslett, C., Davidson, D. J., & Rossi, A. G. (2013). Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps. Journal of Inflammation, 10(1), 12. https://doi.org/10.1186/1476-9255-10-12

Harrison, M. (2015). Erythrocyte sedimentation rate and C-reactive protein. Australian Prescriber, 38(3), 93–94. https://doi.org/10.18773/austprescr.2015.034

Hill, S. J. (1992). Multiple histamine receptors: properties and functional characteristics. Biochemical Society Transactions, 20(1), 122–125. https://doi.org/10.1042/bst0200122

Hofstra, C. L., Desai, P. J., Thurmond, R. L., & Fung-Leung, W.-P. (2003). Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. Journal of Pharmacology and Experimental Therapeutics, 305(3), 1212–1221.

Hudson, N., & Hawkey, C. J. (1993). Non-steroidal anti-inflammatory drug-associated upper gastrointestinal ulceration and complications. European Journal of Gastroenterology & Hepatology, 5(6), 412–419. https://journals.lww.com/euroghj/Fulltext/1993/06000/Non_steroidal_anti_inflammatory_drug_associated.4.aspx

Ingelsson, E., Ärnlöv, J., Sundström, J., & Lind, L. (2005). Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. Journal of the American College of Cardiology, 45(11), 1802–1806. https://doi.org/10.1016/j.jacc.2005.02.066
Jemima, E. A., Prema, A., & Thangam, E. B. (2014). Functional characterization of histamine H4 receptor on human mast cells. *Molecular Immunology, 62*(1), 19–28. https://doi.org/10.1016/j.molimm.2014.05.007

Kilinc, E., Baranoğlu, Y., & Baranoğlu Kilinç, Y. (2020). Mast cell stabilizers as a supportive therapy can contribute to alleviate fatal inflammatory responses and severity of pulmonary complications in COVID-19 infection. *Anadolu Kliniği Tip Bilimleri Dergisi, 25*, 111–118. https://doi.org/10.21673/anadoluklin.720116

Kim, B.-W., Koppula, S., Hong, S.-S., Jeon, S.-B., Kwon, J.-H., Hwang, B.-Y., Park, E.-J., & Choi, D.-K. (2013). Regulation of microglia activity by glauccalyxin-A: attenuation of lipopolysaccharide-stimulated neuroinflammation through NF-κB and p38 MAPK signaling pathways. *PLoS One, 8*(2), e55792.

Kounis, N., Soufras, G., Tsigkas, G., & Hahalis, G. (2014). White Blood Cell Counts, Leukocyte Ratios, and Eosinophils as Inflammatory Markers in Patients With Coronary Artery Disease. *Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 21*. https://doi.org/10.1177/1076029614531449

Kozin, F., McCarty, D. J., Sims, J., & Genant, H. (1976). The reflex sympathetic dystrophy syndrome: I. Clinical and histologic studies: evidence for bilaterality, response to corticosteroids and articular involvement. *The American Journal of Medicine, 60*(3), 321–331.

Kritas, S. K., Ronconi, G., Caraffa, A., Gallenga, C. E., Ross, R., & Conti, P. (2020). Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. In *Journal of biological regulators and homeostatic agents* (Vol. 34, Issue 1, pp. 9–14). https://doi.org/10.23812/20-Editorial-Kritas

Kuratani, T., Nagata, K., Kukita, T., Hotokebuchi, T., Nakasima, A., & Iijima, T. (1998). Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. *Histology and Histopathology, 13*(3), 751–760.

Laine, L., Smith, R., Min, K., Chen, C., & Dubois, R. W. (2006). Systematic review: The lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. *Alimentary Pharmacology and Therapeutics, 22*(5), 751–767. https://doi.org/10.1111/j.1365-2036.2006.03043.x

Li, J., Ke, T., He, C., Cao, W., Wei, M., Zhang, L., Zhang, J.-X., Wang, W., Ma, J., Wang, Z.-R., & Shao, Z.-J. (2010). The Anti-Arthritic Effects of Synthetic Melittin on the Complete Freund’s Adjuvant-Induced Rheumatoid Arthritis Model in Rats. *The American Journal of Chinese Medicine, 38*(06), 1039–1049. https://doi.org/10.1142/S0192415X10008457

Lippert, U., Artuc, M., Grütkau, A., Babina, M., Guhl, S., Haase, I., Blaschke, V., Zachmann, K., Knosalla, M., & Middel, P. (2004). Human skin mast cells express H2 and H4, but not H3 receptors. *Journal of Investigative Dermatology, 123*(1), 116–123.
Lubberts, E., Koenders, M. I., Oppers-Walgreen, B., van den Bersselaar, L., Coenen-de Roo, C. J. J., Joosten, L. A. B., & van den Berg, W. B. (2004). Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. *Arthritis and Rheumatism, 50*(2), 650–659. https://doi.org/10.1002/art.20001

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. *Nature, 454*(7203), 436–444. https://doi.org/10.1038/nature07205

Medina, E. (2009). Neutrophil extracellular traps: a strategic tactic to defeat pathogens with potential consequences for the host. *Journal of Innate Immunity, 1*(3), 176–180.

Mirzahosseini, A., Dalmadi, B., & Csutora, P. (2013). Histamine receptor H4 regulates mast cell degranulation and IgE induced FceRI upregulation in murine bone marrow-derived mast cells. *Cellular Immunology, 283*(1–2), 38–44.

Moore, A. R., & Willoughby, D. A. (1995). The role of cAMP regulation in controlling inflammation. In *Clinical and experimental immunology* (Vol. 101, Issue 3, pp. 387–389). https://doi.org/10.1111/j.1365-2249.1995.tb03123.x

Nasuti, C., Fedeli, D., Bordoni, L., Piangerelli, M., Servili, M., Selvaggini, R., & Gabbianelli, R. (2019). Anti-Inflammatory, Anti-Arthritic and Anti-Nociceptive Activities of Nigella sativa Oil in a Rat Model of Arthritis. *Antioxidants (Basel, Switzerland), 8*(9), 342. https://doi.org/10.3390/antiox8090342

Niki, Y., Matsumoto, H., Hakozaki, A., Mochizuki, T., & Momohara, S. (2010). Rheumatoid arthritis: a risk factor for deep venous thrombosis after total knee arthroplasty? Comparative study with osteoarthritis. *Journal of Orthopaedic Science, 15*(1), 57–63.

Oldenburger, A., Roscioni, S. S., Jansen, E., Menzen, M. H., Halayko, A. J., Timens, W., Meurs, H., Maarsingh, H., & Schmidt, M. (2012). Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. *PloS One, 7*(2), e31574.

Ong, E., Farran, S., Salloum, M., Gardner, S., Giovinco, N., Armstrong, D., Nix, D., & Al Mohajer, M. (2015). The Role of Inflammatory Markers: WBC, CRP, ESR, and Neutrophil-to-Lymphocyte Ratio (NLR) in the Diagnosis and Management of Diabetic Foot Infections. *Open Forum Infectious Diseases, 2*. https://doi.org/10.1093/ofid/ofv133.1079

Pahwa, R., & Jialal, I. (2019). *Chronic inflammation*.

Ramprasath, V. R., Shanthi, P., & Sachdanandam, P. (2006). Immunomodulatory and anti-inflammatory effects of Semecarpus anacardium LINN. Nut milk extract in experimental inflammatory conditions. *Biological & Pharmaceutical Bulletin, 29*(4), 693–700. https://doi.org/10.1248/bpb.29.693

Ray, M. A., Johnston, N. A., Verhulst, S., Trammell, R. A., & Toth, L. A. (2010). Identification of markers for imminent death in mice used in longevity and aging research. *Journal of the American Association for Laboratory Animal Science, 49*(3), 282–288.

Rein, P., & Mueller, R. B. (2017). Treatment with biologicals in rheumatoid arthritis: an overview. *Rheumatology and Therapy, 4*(2), 247–261.
Ren, J., Chen, X., & Chen, Z. J. (2014). IKKβ is an IRF5 kinase that instigates inflammation. *Proceedings of the National Academy of Sciences, 111*(49), 17438–17443.

Saeki, M., Nishimura, T., Kaminuma, O., Ohtsu, H., Mori, A., & Hiroi, T. (2016). Crosstalk Between Histamine and T Cells in Allergic Diseases. *Current Immunology Reviews, 12*(4), 10–13. https://doi.org/10.2174/1573395511666150706180936

Schaefer, U., Schmitz, V., Schneider, A., & Neugebauer, E. (1999). Histamine induced homologous and heterologous regulation of histamine receptor subtype mRNA expression in cultured endothelial cells. *Shock (Augusta, Ga.), 12*(4), 309–315. https://doi.org/10.1097/00024382-199910000-00010

Shenker, N., Haigh, R., Roberts, E., Mapp, P., Harris, N., & Blake, D. (2003). A review of contralateral responses to a unilateral inflammatory lesion. *Rheumatology, 42*(11), 1279–1286.

Simons, F. E. R. (2004). Advances in H1-antihistamines. *The New England Journal of Medicine, 351*(21), 2203–2217. https://doi.org/10.1056/NEJMra033121

Stils Jr., H. F. (2005). Adjuvants and Antibody Production: Dispelling the Myths Associated with Freund's Complete and Other Adjuvants. *ILAR Journal, 46*(3), 280–293. https://doi.org/10.1093/ilar.46.3.280

Straub, R. H., & Schradin, C. (2016). Chronic inflammatory systemic diseases – an evolutionary trade-off between acutely beneficial but chronically harmful programs. *Evolution, Medicine, and Public Health, 37*–51. https://doi.org/10.1093/emph/eow001

Suzuki, N., Kitamura, K., Nemoto, T., Shimizu, N., Wada, S., Kondo, T., Tabata, M. J., Sodeyama, F., Ijiri, K., & Hattori, A. (2007). Effect of vibration on osteoblastic and osteoclastic activities: Analysis of bone metabolism using goldfish scale as a model for bone. *Advances in Space Research, 40*(11), 1711–1721.

Tamaka, K., Seike, M., Hagiwara, T., Sato, A., & Ohtsu, H. (2015). Histamine suppresses regulatory T cells mediated by TGF-β in murine chronic allergic contact dermatitis. *Experimental Dermatology, 24*(4), 280–284.

Thangam, E. B., Jemima, E. A., Singh, H., Baig, M. S., Khan, M., Mathias, C. B., Church, M. K., & Saluja, R. (2018). The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets. *Frontiers in Immunology, 9*, 1873. https://doi.org/10.3389/fimmu.2018.01873

van den Berg, W. B. (2001). Uncoupling of inflammatory and destructive mechanisms in arthritis. *Seminars in Arthritis and Rheumatism, 30*(5 Suppl 2), 7–16. https://doi.org/10.1053/sarh.2001.23704

Voon, V., Napier, T. C., Frank, M. J., Sgambato-Faure, V., Grace, A. A., Rodriguez-Oroz, M., Obeso, J., Bezard, E., & Fernagut, P.-O. (2017). Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. *The Lancet Neurology, 16*(3), 238–250. https://doi.org/https://doi.org/10.1016/S1474-4422(17)30004-2

Walsh, N. C., Crotti, T. N., Goldring, S. R., & Gravallese, E. M. (2005). Rheumatic diseases: the effects of inflammation on bone. *Immunological Reviews, 208*, 228–251. https://doi.org/10.1111/j.0105-2896.2005.00338.x

Wang, L., Guo, T., Guo, Y., & Xu, Y. (2020). Asiaticoside produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in mice, involving reversion of inflammation and the
PKA/pCREB/BDNF signaling pathway. *Molecular Medicine Reports, 22*(3), 2364–2372. https://doi.org/10.3892/mmr.2020.11305

Watson, J., Round, A., & Hamilton, W. (2012). Raised inflammatory markers. *BMJ (Clinical Research Ed.), 344*, e454. https://doi.org/10.1136/bmj.e454

Wilhelm, D. L. (1973). Mechanisms responsible for increased vascular permeability in acute inflammation. *Agents and Actions, 3*(5), 297–306. https://doi.org/10.1007/BF01986484

Williams, J. P., & Meyers, J. A. (2002). Immune-mediated inflammatory disorders (IMIDs): the economic and clinical costs. *American Journal of Managed Care, 8*(21; SUPP), S664–S681.

Xu, J., Stanislaus, S., Chinookoswong, N., Lau, Y. Y., Hager, T., Patel, J., Ge, H., Weiszmann, J., Lu, S.-C., Graham, M., Busby, J., Hecht, R., Li, Y.-S., Li, Y., Lindberg, R., & Véniant, M. M. (2009). Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects. *American Journal of Physiology. Endocrinology and Metabolism, 297*(5), E1105-14. https://doi.org/10.1152/ajpendo.00348.2009

Xue, R., Dong, L., Zhang, S., Deng, C., Liu, T., Wang, J., & Shen, X. (2008). Investigation of volatile biomarkers in liver cancer blood using solid-phase microextraction and gas chromatography/mass spectrometry. *Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up-to-the-Minute Research in Mass Spectrometry, 22*(8), 1181–1186.

Yu, M., Nishiyama, A., Trapp, B. D., & Tuohy, V. K. (1996). Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. *Journal of Neuroimmunology, 64*(1), 91–100.

Zatroch, K. K., Knight, C. G., Reimer, J. N., & Pang, D. S. J. (2017). Refinement of intraperitoneal injection of sodium pentobarbital for euthanasia in laboratory rats (Rattus norvegicus). *BMC Veterinary Research, 13*(1), 60. https://doi.org/10.1186/s12917-017-0982-y

Zhang, W., & Anis, A. H. (2011). The economic burden of rheumatoid arthritis: beyond health care costs. *Clinical Rheumatology, 30*(1), 25–32.

Zhong, J., & Shi, G. (2019). Editorial: Regulation of Inflammation in Chronic Disease. In *Frontiers in Immunology* (Vol. 10, p. 737). https://www.frontiersin.org/article/10.3389/fimmu.2019.00737.

**Tables**

| Table 1: | Radiologic score of adjuvant-induced arthritic rats |
Sprague-Dawley rats were injected sub plantar with 0.1 ml of IFA or CFA into the right hind paw. The drug vehicle, dexamethasone (0.3 mg/kg) and HFE (50, 200, 500 mg/kg) were administered orally 1 h before arthritis induction and thereafter until the 28th day in the prophylactic approach and started on the 14th day after the induction of arthritis and daily till the 28th day in the therapeutic approach. Rats were euthanized by cervical dislocation and radiographs taken. The extent of peri-articular swelling, osteolysis and joint damage of the radiographs were blindly scored by a radiologist on a scale of 0-3, where 0: no damage; 1: mild; 2: moderate; and 3: severe. Values shown are mean of n ≥ 5.

Table 2: Histology scores on micrographs of paw sections from control and adjuvant-induced arthritic Sprague-Dawley rats

| Histology score                  | Prophylactic | Therapeutic |
|----------------------------------|--------------|-------------|
| IFA                              | 0            | 0           |
| CFA                              | 3            | 3           |
| Dexamethasone (0.3 mg/kg)        | 1            | 1           |
| HFE (50 mg/kg)                   | 2            | 2           |
| HFE (200 mg/kg)                  | 2            | 2           |
| HFE (500 mg/kg)                  | 1            | 1           |

Sprague-Dawley rats were injected sub plantar with 0.1 ml of IFA or CFA into the right hind paw. The drug vehicle, dexamethasone (0.3 mg/kg) and HFE (50, 200, 500 mg/kg) were administered orally 1 h before arthritis induction and thereafter until the 28th day in the prophylactic approach and started on the 14th day after the induction of arthritis and daily till the 28th day in the therapeutic approach. Rats were euthanized by cervical dislocation and radiographs taken. The extent of peri-articular swelling, osteolysis and joint damage of the radiographs were blindly scored by a radiologist on a scale of 0-3, where 0: no damage; 1: mild; 2: moderate; and 3: severe. Values shown are mean of n ≥ 5.
paw. The drug vehicle, dexamethasone (0.3 mg/kg) and HFE (50, 200, 500 mg/kg) were administered orally 1 h before arthritis induction and thereafter until the 28th day in the prophylactic approach and started on the 14th day after the induction of arthritis and daily till the 28th day in the therapeutic approach. The rats were euthanized by cervical dislocation. Bone tissue of the right hind limbs were sectioned, stained with haematoxylin-eosin and micrographs of the tissue were captured and scored on a scale of 0 – 3: (0) absence of inflammation indicators; (1) mild inflammation; (2) moderate inflammation; (3) inflammation. Values shown are mean of n ≥ 5.

Table 3: Effect of treatment on haematological profile of adjuvant-induced arthritic rats

|                      | WBC (x10³/μL) | RBC (x10⁶/μL) | HGB (g dL⁻¹) | HCT (%) | ESR (mm/h) |
|----------------------|---------------|---------------|--------------|---------|------------|
| **Control**          |               |               |              |         |            |
| IFA                  | 13.58 ± 1.25  | 8.18 ± 0.14   | 15.15 ± 0.22 | 47.15 ± 0.79 | 0.40 ± 0.24 |
| CFA untreated        | 18.94 ± 0.85  | 6.83 ± 0.395  | 12.96 ± 0.25 | 40.26 ± 1.33 | 10.00 ± 1.87 |
| **Prophylactic**     |               |               |              |         |            |
| Dexamethasone        | 7.00±0.56¥    | 8.31±0.18     | 14.74±0.25   | 45.34±0.97# | 2.20 ± 0.94# |
| HFE (50 mg/kg)       | 16.65±1.8     | 7.81±0.14     | 13.85±0.18   | 42.38±0.86  | 6.50±1.19   |
| HFE (200mg/kg)       | 14.68±0.2*    | 8.08±0.22     | 14.80±0.37   | 45.35±0.87** | 3.40±0.93¥ |
| HFE (500mg/kg)       | 13.97±1.32**  | 8.29±0.26     | 14.96±0.11   | 46.24±0.27¥ | 1.60±0.68¥ |
| **Therapeutic**      |               |               |              |         |            |
| Dexamethasone        | 15.50±1.61    | 8.76±0.22     | 15.48±0.42   | 48.33±1.62  | 2.10±0.10¥ |
| HFE (50 mg/kg)       | 18.78±0.75    | 7.86±0.39     | 14.83±0.44   | 43.93±2.22  | 6.40±0.81   |
| HFE (200mg/kg)       | 17.55±1.14    | 7.94±0.10     | 14.33±0.24   | 44.43±0.44* | 4.00±0.55¥ |
| HFE (500mg/kg)       | 15.50±0.39    | 8.19±0.21     | 15.45±0.57   | 47.00±0.35¥ | 2.20±0.37¥ |

Sprague-Dawley rats were injected sub plantar with 0.1 ml of IFA or CFA into the right hind paw. The drug vehicle, dexamethasone (0.3 mg/kg) and HFE (50, 200, 500 mg/kg) were administered orally 1 h before arthritis induction and thereafter until the 28th day in the prophylactic approach and started on the 14th day after the induction of arthritis and daily till the 28th day in the therapeutic approach. Blood was collected from the tail vein on day 28 and a full blood count was done using a haem analyser. Erythrocyte sedimentation rate (ESR) was determined using the standard Westergren method. Data presented show mean ± S.E.M for n ≥ 5. * (P ≤ 0.05), ** (P ≤ 0.01), # (P ≤ 0.001), ¥ (P ≤ 0.0001) values significantly different when compared with CFA arthritic control.
Plates

Plates 1-3 are available in the Supplementary Files.